Main Products
Chugai’s prescribed medicines are categorized into oncology, specialty (excl. oncology), and products out-licensed to third parties.
View details in a PDF format.
Oncology Area
| Alecensa (alectinib) | ALK inhibitor |
|---|---|
| Avastin (bevacizumab) | Anti-VEGF humanized monoclonal antibody |
| FoundationOne CDx Cancer Genomic Profile FoundationOne Liquid CDx Cancer Genomic Profile |
- |
| Kadcyla (trastuzumab emtansine) | Anti-HER2 antibody-tubulin polymerization inhibitor conjugate |
| Lunsumio (mosunetuzumab) | Anti-CD20/CD3 humanized bispecific antibody |
| Perjeta (pertuzumab) | Anti-HER2 humanized monoclonal antibody |
| Phesgo (pertuzumab, trastuzumab and vorhyaluronidase alfa) | Anti-HER2 humanized monoclonal antibody/hyaluronandegradation enzyme combination |
| Polivy (polatuzumab vedotin) | Antimicrotubule binding anti-CD79b monoclonal antibody |
| Tecentriq (atezolizumab) | Anti-PD-L1 humanized monoclonal antibody |
Specialty Area (excl. Oncology)
| Actemra (tocilizumab) | Humanized anti-human IL-6 receptor monoclonal antibody |
|---|---|
| CellCept (mycophenolate mofetil) | Immunosuppressant |
| Elevydis (delandistrogene moxeparvovec) | Microdystrophin gene therapy |
| Enspryng (satralizumab) | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody |
| Evrysdi (risdiplam) | Spinal muscular atrophy agent |
| Hemlibra (emicizumab) | Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody |
| PiaSky (crovalimab) | pH-dependent binding humanized anti-complement (C5) monoclonal antibody |
| Tamiflu (oseltamivir) | Anti-influenza agent |
| Vabysmo (faricimab) | Anti VEGF/anti Ang-2 bispecific antibody |
Products Out-Licensed to Third Parties
| Mitchga / NEMLUVIO (nemolizumab) | Humanized anti-human IL-31 receptor A monoclonal antibody |
|---|---|
| AVMAPKI (avutometinib) | RAF/MEK clamp |